Lexington, Ky. – US Equestrian (USEF) announced today that, beginning June 15, 2018, all medroxyprogesterone acetate (MPA) disclosure forms will be required to be submitted electronically. More information on how to submit the electronic form online can be found here.
Currently, USEF offers the option for both electronic and paper submissions of the MPA disclosure forms. However, on June 15 the electronic submission will be the only disclosure form that will be accepted by USEF.
The use of MPA, also known as the human product Depo-Provera®, currently is permitted at USEF-licensed national competitions. As a reminder, MPA is not permitted for use in FEI competitions. In an effort to better understand the use of MPA in horses competing at US Equestrian competitions, the collection of the MPA disclosure forms will continue to allow for a gathering of pharmacokinetic data in relation to the administration of MPA, including how long it lasts in horses’ systems.
If a horse has received MPA and is competing at a USEF-licensed competition, an electronic MPA disclosure form must be completed. Exhibitors can locate the electronic MPA form here. The MPA Disclosure Form FAQ can be found online to assist with additional inquiries and questions.
It should be noted that an MPA disclosure form does not replace a Medication Report Form (MRF). An MRF should be filled out separately for all other medications, according to USEF Drugs and Medications rules and regulations.